Lana Pine

Jeffrey Sparks, MD, MMSc, discusses what rheumatologists need to know about treating challenging cases of rheumatoid arthritis as well as the risks and benefits of more aggressive treatment strategies.

Jeffrey Sparks, MD, MMSc, explains how to tailor rheumatoid arthritis treatment for an individual patient’s needs and when to consider switching or intensifying treatment.

Yvonne C. Lee, MD, MMSc, explains the pain mechanisms in rheumatic disease and the promising advancements in pain research.

Susan Goodman, MD, discusses pre and perioperative management of rheumatic disease.

A switch from a biologic treatment to a biosimilar demonstrated comparable effects for both primary and co-primary outcomes in patients with rheumatoid arthritis.

After stratifying for gender, age, and ethnicity, hyperuricemia remained positively associated with nephrolithiasis.

Patients receiving TNF, JAK, and CTLA4-Ig all demonstrated higher discontinuation rates due to ineffectiveness when compared to aIL-6R treatment.

Markets with an increased number of rheumatologists had lower costs per patient for emergency room visits and hospitalization compared to areas with a low supply.

A higher pain score and a higher active joint count were shown to be predictive of higher pain over time.

A low certainty of clinically relevant positive effects of aerobic and mixed exercise training for reducing mobility difficulties was observed in patients with fibromyalgia at the end of the intervention.

The subscales presenting the highest scores in patients with fibromyalgia were foot pain and symptom intensity.

Cardiorespiratory and muscular parameters were improved after exercise rehabilitation in patients with long COVID, patients with fibromyalgia, and those with coronary artery disease.

Reduced 12-month drug retention rates were seen in patients with concurrent use of hydroxychloroquine, intravenous bDMARD use, and a history of discontinuation of the drug within the first 3 months of the pandemic.

The strongest predictors of hyperuricemia were body mass index, lipid accumulation product, and visceral adiposity index.

No statistical differences in pain or quality of life were observed between patients with fibromyalgia receiving posterior tibial nerve stimulation intervention and controls.

At week 24, patients receiving guselkumab had significant decreases in C-reactive protein and effector cytokines linked to the interleukin-23 (IL-23)/IL-17 levels compared with patients in the placebo cohort.

Disease activity improved by week 16 in patients receiving CT-P13 and was maintained through the end of the treatment period.

Although gout was not associated with hearing loss, hyperuricemia was significantly linked to impairment.

Osteoporosis is estimated to affect 595 million patients worldwide, representing a 132% increase in total cases since 1990.

Guidelines aim to help the identification of ILD in patients with rheumatic disease and aid in improving the management of patients.

Patients with fibromyalgia reported poorer subjective sleep quality compared with controls, although accelerometry parameters showed no significant differences between groups.

Findings demonstrated Danggui Niantong Decoction combined with conventional Western medicine was more effective in treating gout than Western medicine alone.

Although patients in both the intervention and control cohorts gained weight, patients treated with glucocorticoids gained an average of 1.1 kg more than controls.

Findings reveal a need for distinct strategies to prevent cardiovascular events in patients with rheumatoid arthritis and psoriatic arthritis.

The study met its primary endpoint of PASI improvement in the biosimilar and bio-originator cohorts.

Enhancing access to biosimilars in the US involves multiple key factors, including active participation from payers, providers, and the healthcare community to incentivize the utilization of biosimilars.

Several key initiatives designed to streamline and enhance the efficiency of biosimilar development in the US market are underway, underscoring the timeliness of the Biosimilars Forum's recent report.

Treatment with follitropin alfa resulted in a higher proportion of patients with good quality embryos and higher pregnancy rates when compared with the biosimilar group.

Juliana Reed, MS, discusses the recent publication of a peer-reviewed report by the Biosimilars Forum on the future trajectory of biosimilar development and its applications.

At weeks 12 and 24, the proportion of patients reporting high disease activity reduced from 16.7% to 8.3%, respectively.